TY - JOUR
T1 - Nationwide laboratory based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011
AU - Lambertsen, Lotte Munch
AU - Ingels, Helene
AU - Schønheyder, Henrik Carl
AU - Hoffmann, Steen
AU - The Danish Streptococcal Surveillance Collaboration Group 2011
AU - Hoffmann, Steen
AU - Ingels, Helene
AU - Lambertsen, Lotte Munch
AU - Christensen, Jens Jørgen
AU - Dessau, Ram
AU - Lomborg, Steen
AU - Schønheyder, Henrik Carl
AU - Tvede, Michael
AU - Østergaard, Christian
N1 - This article is protected by copyright. All rights reserved.
PY - 2014
Y1 - 2014
N2 - The aim of this work was to describe national surveillance of invasive beta-haemolytic streptococci (BHS) in Denmark and to report over-all trends and major findings by groups and types of BHS causing laboratory confirmed disease from 2005 to 2011.Results:A total of 3,063 BHS isolates were received from 2,872 patients. Based on confirmed cases the over-all annual incidence increased from 6.2 to 8.9 per 100,000 persons from 2005 to 2011. In 2011 the incidences of group A, B, C and G streptococci were 3.1, 2.3, 0.9 and 2.6 per 100,000 persons, respectively. An increase was observed for all groups of BHS, but in particular for group G in men above 65 years of age. Among group A streptococci (GAS), five T-types (1; 28; 12; 3,13,B3264; B3264) represented 71% and five emm-types (1, 28, 3, 89, 12) 76% of all isolates. Among group B streptococci (GBS) four types (III, Ia, V, Ib) represented 79% of the isolates. Potential coverage for future vaccines against GAS and GBS disease was 76% compared to the 26-valent GAS vaccine and 89% based on GBS serotypes Ia, Ib, II, III and V, respectively.Conclusion:The number of reported cases of invasive BHS disease increased in Denmark from 2005 to 2011. Nationwide laboratory based surveillance of BHS is required to monitor epidemiological changes, explore potential outbreaks, and determine potential vaccine coverage. This article is protected by copyright. All rights reserved.
AB - The aim of this work was to describe national surveillance of invasive beta-haemolytic streptococci (BHS) in Denmark and to report over-all trends and major findings by groups and types of BHS causing laboratory confirmed disease from 2005 to 2011.Results:A total of 3,063 BHS isolates were received from 2,872 patients. Based on confirmed cases the over-all annual incidence increased from 6.2 to 8.9 per 100,000 persons from 2005 to 2011. In 2011 the incidences of group A, B, C and G streptococci were 3.1, 2.3, 0.9 and 2.6 per 100,000 persons, respectively. An increase was observed for all groups of BHS, but in particular for group G in men above 65 years of age. Among group A streptococci (GAS), five T-types (1; 28; 12; 3,13,B3264; B3264) represented 71% and five emm-types (1, 28, 3, 89, 12) 76% of all isolates. Among group B streptococci (GBS) four types (III, Ia, V, Ib) represented 79% of the isolates. Potential coverage for future vaccines against GAS and GBS disease was 76% compared to the 26-valent GAS vaccine and 89% based on GBS serotypes Ia, Ib, II, III and V, respectively.Conclusion:The number of reported cases of invasive BHS disease increased in Denmark from 2005 to 2011. Nationwide laboratory based surveillance of BHS is required to monitor epidemiological changes, explore potential outbreaks, and determine potential vaccine coverage. This article is protected by copyright. All rights reserved.
U2 - 10.1111/1469-0691.12378
DO - 10.1111/1469-0691.12378
M3 - Journal article
C2 - 24125634
SN - 1198-743X
VL - 20
SP - O216-O223
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 4
ER -